Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

June 8, 2022

Study Completion Date

July 5, 2022

Conditions
Peripheral NeuropathyChemotherapy-induced Peripheral NeuropathyBreast Cancer
Interventions
DRUG

Lidocaine in Saline

Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.

DRUG

Duloxetine 30 MG

Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month

DRUG

Normal saline

200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.

Trial Locations (1)

Unknown

Egypt Medical Research Institute, Alexandria

All Listed Sponsors
lead

Gamal Mohamed Taha Abouelmagd

OTHER

NCT04732455 - Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients | Biotech Hunter | Biotech Hunter